Offers xRNA and LNP services, including mRNA drug substance, LNPs, and ATMP fill-finish. The current provider, brand, and manufacturing site require confirmation.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Offers xRNA and LNP services, including mRNA drug substance, LNPs, and ATMP fill-finish. The current provider, brand, and manufacturing site require confirmation.
Offers oral solid dosage development linking formulation, process development, and risk assessment with the QTPP, for clinical and commercial supply.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| RNA / LNP service capabilities | Project-dependent / not verified · Project-dependent / not verified | Services / platform | This record does not establish human validation of the entire platform |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Recipharm has added a sterile cream and ointment line at its Odivelas site in Portugal. The line accommodates aluminum and polyfoil tubes from 3.5 to 30 grams, with annual output of 8 million to 15 million units depending on fill volume and batch size. It complements existing multidose ophthalmic manufacturing and is ready for new customer projects.
Recipharm has extended high-potency oral solid dose manufacturing at Leganés, Spain, to GMP pilot scale. A contained suite combines dry granulation, tableting, and coating for compounds up to OEB 5. The same pilot equipment can support clinical and small commercial batches, with larger programs transferring to commercial lines at the same site rather than another facility.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Moderna announced Canadian authorization of mFLUSIVA, its mRNA influenza vaccine, and mCOFLU, its combined influenza and COVID-19 vaccine, for adults 50 and older. The November 5 announcement cites Phase 3 efficacy evidence for mFLUSIVA and immunogenicity comparisons for mCOFLU. The company said it would engage Canadian authorities and immunization partners on future availability.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.